Pacific Edge Limited

Pacific Edge Limited is a cancer diagnostics New Zealand company that offers a genetic biomarker based suite of bladder cancer diagnostic tools. The company has offices in Hershey, USA, and its head office in Dunedin, New Zealand. Pacific Edge is listed on the New Zealand NZX main board stock exchange under ticker code PEB, and forms part of the NZX 50 Index.[3]

Pacific Edge Limited
TypePublic
NZX: PEB
IndustryCancer diagnostics
Founded2001
Headquarters
Dunedin, New Zealand and Hershey, USA
Area served
New Zealand, Australia, Spain, United States of America
Key people
David Darling[1][2] (Group CEO) and Jackie Walker (CEO of Pacific Edge Diagnostics USA)
ProductsCxBladder Suite of bladder cancer diagnostics tools
ServicesUrology
Revenue$4m as at November 2015
Number of employees
Approx 50 globally
Websitepacificedgedx.com

History

Established in August 2001,[4] Pacific Edge uses genetic biomarkers in urine to detect the presence of cancer. They market themselves as being a third less expensive than other diagnostic tools.[5]

They provide a diagnostic service through their facilities in New Zealand and the United States as well as selected partners in Europe and Australia.

The firm is listed on the New Zealand NZX index. They have had a number of capital raises, most recently in 2013 and 2015 to pursue commercialisation of their diagnostic tests in the USA.[6]

In June 2020, Pacific Edge secured a commercial relationship with Kaiser Permanente, one of the largest health insurance providers in the US, for its bladder cancer tests.[7]

Products

Pacific Edge's suite of tests for bladder cancer are called CxBladder, with specialist sub-type products to detect cancerous cells and provide triage for clinicians and oncologists.[8] Their tests samples are non-invasive urine test based on RNA and protein assays, with high sensitivity and earlier detection than other forms of bladder cancer diagnostics like cytology.[9][10][11][12][13][14]

Awards

Pacific Edge has won a number of awards, including

References
  1. "PEB.NZ Profile - Pacific Edge Limited Ordinary S Stock - Yahoo! Finance". Yahoo! Finance. Retrieved 31 December 2015.
  2. "Pacific Edge first-half loss widens". The New Zealand Herald. Retrieved 31 December 2015.
  3. "Pacific Edge Limited". Retrieved 31 December 2015.
  4. "NZX Main Board - PEB Analysis". NZX. Retrieved 31 December 2015. Pacific Edge Limited (PEB) was formed in August 2001 following acquisition of intellectual property from the University of Otago.
  5. "Pacific Edge shares soar to new high". New Zealand Herald. 2013-10-22. ISSN 1170-0777. Retrieved 2015-12-31.
  6. "Pacific Edge seeks $35.3M to fund US growth". The New Zealand Herald. Retrieved 31 December 2015.
  7. "Kaiser Permanente Approves Commercial Use of Cxbladder - NZX, New Zealand's Exchange". www.nzx.com. Retrieved 2020-06-25.
  8. "Suite of cancer products grows". Otago Daily Times. Retrieved 31 December 2015.
  9. Alan Wood (27 May 2015). "Pacific Edge's FY loss widens to $10.58m, plans to raise $35.3m". Stuff.co.nz. Retrieved 31 December 2015.
  10. Janis C. Kelly (26 October 2015). "Urinary Biomarkers Not Useful for Bladder Cancer Diagnosis". Medscape. Retrieved 31 December 2015.
  11. MARTA STEEMAN (9 June 2015). "Singapore hospital to trial Pacific Edge's main bladder cancer detection product". Stuff.co.nz. Retrieved 31 December 2015.
  12. "Warning over bladder cancer test". Stuff.co.nz. Retrieved 31 December 2015.
  13. "Pacific Edge sales up; still no profit". Otago Daily Times. Retrieved 31 December 2015.
  14. "Pacific Edge gets US approval for Dunedin laboratory". The New Zealand Herald. Retrieved 31 December 2015.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.